ICU Medical (NASDAQ:ICUI) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of ICU Medical (NASDAQ:ICUI) from a sell rating to a hold rating in a research report sent to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “ICU Medical, Inc. develops, manufactures and sells innovative medical devices used in vascular therapy, oncology and critical care applications. They are one of the world’s leading pure-play infusion therapy companies, with global operations and a wide-ranging product portfolio that includes IV solutions, IV smart pumps, dedicated and non-dedicated IV sets and needlefree connectors, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. In addition, they manufacture automated pharmacy IV compounding systems with workflow technology, closed systems transfer devices for hazardous IV drugs, and cardiac monitoring systems to optimize patient fluid levels. “

Several other brokerages have also recently issued reports on ICUI. BidaskClub cut shares of Zebra Technologies from a hold rating to a sell rating in a report on Friday, May 24th. TheStreet cut shares of USD Partners from a b- rating to a c+ rating in a report on Friday, May 10th. Three research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. ICU Medical currently has a consensus rating of Buy and a consensus price target of $281.00.

Shares of ICU Medical stock opened at $248.80 on Wednesday. The stock has a market capitalization of $5.08 billion, a PE ratio of 32.27 and a beta of 0.82. ICU Medical has a 52-week low of $210.94 and a 52-week high of $321.70. The business has a 50-day moving average price of $238.23.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, May 9th. The medical instruments supplier reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.39. The business had revenue of $330.93 million during the quarter, compared to analysts’ expectations of $318.97 million. ICU Medical had a net margin of 4.04% and a return on equity of 13.70%. The business’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.26 earnings per share. As a group, analysts predict that ICU Medical will post 8.55 earnings per share for the current year.

In other news, COO Christian B. Voigtlander sold 5,348 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $227.59, for a total transaction of $1,217,151.32. Following the completion of the transaction, the chief operating officer now directly owns 4,732 shares of the company’s stock, valued at $1,076,955.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin J. Mcgrody sold 7,344 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $231.68, for a total transaction of $1,701,457.92. Following the transaction, the insider now directly owns 7,574 shares of the company’s stock, valued at $1,754,744.32. The disclosure for this sale can be found here. Insiders have sold 37,692 shares of company stock valued at $9,168,609 over the last three months. 11.40% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Smith Moore & CO. purchased a new position in shares of ICU Medical during the fourth quarter valued at approximately $254,000. Amalgamated Bank increased its holdings in ICU Medical by 59.6% during the fourth quarter. Amalgamated Bank now owns 3,660 shares of the medical instruments supplier’s stock valued at $840,000 after buying an additional 1,367 shares during the last quarter. Rhumbline Advisers increased its holdings in ICU Medical by 1.3% during the first quarter. Rhumbline Advisers now owns 45,901 shares of the medical instruments supplier’s stock valued at $10,985,000 after buying an additional 575 shares during the last quarter. Texas Permanent School Fund increased its holdings in ICU Medical by 3.8% during the first quarter. Texas Permanent School Fund now owns 11,274 shares of the medical instruments supplier’s stock valued at $2,698,000 after buying an additional 414 shares during the last quarter. Finally, Raymond James Trust N.A. increased its holdings in ICU Medical by 47.4% during the first quarter. Raymond James Trust N.A. now owns 1,480 shares of the medical instruments supplier’s stock valued at $354,000 after buying an additional 476 shares during the last quarter. 90.05% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

See Also: Bear Market – How and Why They Occur

Get a free copy of the Zacks research report on ICU Medical (ICUI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.